Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Why This Illumina Analyst Is Bullish About NovaSeq X+

Published 04/10/2022, 17:32
Updated 04/10/2022, 18:10
© Reuters.  Why This Illumina Analyst Is Bullish About NovaSeq X+

© Reuters. Why This Illumina Analyst Is Bullish About NovaSeq X+

Illumina, Inc.’s (NASDAQ: ILMN) NovaSeq X Plus is likely to become “the ultimate genome machine,” lending upside in 2024 and beyond, according to SVB Securities.

The Illumina Analyst: Puneet Souda upgraded the rating for Illumina from Market Perform to Outperform, while raising the price target to $270.

The Illumina Thesis: NovaSeq X Plus could become the instrument of choice “as both the clinical and research end-markets pivot from panels and exomes to whole genomes, while the backdrop of MRD and cancer screening samples only grows,” Souda said in the upgrade note.

Check out other analyst stock ratings.

This product could catalyze the transition over the next three to four years and generate $1.5 million to $1.8 million, “with strong X+ installs replacing the existing 1500 high volume NovaSeq 6k and bringing in new customers,” the analyst added.

Illumina served a total addressable market of $120 billion and was “about to benefit from major expansion in its latest HT cycle,” he further mentioned.

ILMN Price Action: Shares of Illumina had risen by 9.47% to $204.97 at the time of publication Tuesday.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.